Hepta Bio develops liquid biopsy diagnostics for chronic disease, initially targeting metabolic dysfunction-associated steatohepatitis (MASH)
Hepta Bio develops liquid biopsy diagnostics for chronic disease, initially targeting metabolic dysfunction-associated steatohepatitis (MASH). Its LiquidTransformer AI platform analyzes epigenetic patterns in cell-free DNA to infer tissue-level biology from blood, identify patients with clinically significant liver fibrosis, and assess potential therapy response.